Boston Scientific (NYSE: BSX): Analyst Views Diverge as Earnings Outlook Remains Uncertain
- Wells Fargo lowered its price target from $50 to $48 while maintaining an Equal Weight rating.
- Brokerage recommendations remained broadly favorable in a September 11 survey, but Zacks’ separate earnings-based ranking was bearish later that month.
- A recent cybersecurity incident has added uncertainty to Boston Scientific’s 2026 earnings outlook, making valuation estimates harder to interpret.
Boston Scientific (NYSE: BSX) develops medical devices used in cardiovascular care, digestive health and pain management. Its shares closed at $44.62 on September 23, 2026.
On September 23, Wells Fargo analyst Larry Biegelsen reduced his price target to $48 from $50 and maintained an Equal Weight rating. Compared with the September 23 closing price, that target represents approximately 7.6% potential upside. A price target is an analyst’s estimate, not a forecast of a guaranteed return.
On September 11, Zacks reported an average brokerage recommendation of 1.53 from 30 firms, between Strong Buy and Buy on its five-point scale. Its separate Zacks Rank was #5 (Strong Sell) at that time, reflecting earnings-estimate revisions.
A Seeking Alpha contributor also upgraded their opinion to Strong Buy and cited a forward price-to-earnings ratio of 13.1. On September 8, Boston Scientific said a cybersecurity incident made it unlikely to meet its previously issued third-quarter and full-year 2026 sales-growth and adjusted-earnings guidance.
